ACLARIS THERAPEUTICS INC (ACRS)
US00461U1051 - Common Stock
We assign a fundamental rating of 3 out of 10 to ACRS. ACRS was compared to 198 industry peers in the Pharmaceuticals industry. The financial health of ACRS is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ACRS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ACRS has reported negative net income.
ACRS had a negative operating cash flow in the past year.
In the past 5 years ACRS always reported negative net income.
In the past 5 years ACRS always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ACRS (-44.82%) is comparable to the rest of the industry.
ACRS has a Return On Equity (-56.29%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.82% | ||
| ROE | -56.29% | ||
| ROIC | N/A |
ROA(3y)-38.38%
ROA(5y)-70.27%
ROE(3y)-48.78%
ROE(5y)-102.5%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ACRS (42.15%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of ACRS has grown nicely.
The Profit Margin and Operating Margin are not available for ACRS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.15% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y26.47%
GM growth 5Y7.32%
2. Health
2.1 Basic Checks
ACRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACRS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ACRS has more shares outstanding
There is no outstanding debt for ACRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ACRS has an Altman-Z score of -4.79. This is a bad value and indicates that ACRS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.79, ACRS is not doing good in the industry: 63.08% of the companies in the same industry are doing better.
ACRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.79 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
A Current Ratio of 4.16 indicates that ACRS has no problem at all paying its short term obligations.
ACRS has a Current ratio (4.16) which is comparable to the rest of the industry.
A Quick Ratio of 4.16 indicates that ACRS has no problem at all paying its short term obligations.
ACRS has a better Quick ratio (4.16) than 60.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.16 | ||
| Quick Ratio | 4.16 |
3. Growth
3.1 Past
ACRS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.02%.
Looking at the last year, ACRS shows a small growth in Revenue. The Revenue has grown by 5.04% in the last year.
The Revenue has been growing by 38.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)6.02%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q95.12%
Revenue 1Y (TTM)5.04%
Revenue growth 3Y68.95%
Revenue growth 5Y38.42%
Revenue growth Q2Q126.71%
3.2 Future
Based on estimates for the next years, ACRS will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.35% on average per year.
The Revenue is expected to grow by 15.34% on average over the next years. This is quite good.
EPS Next Y19.57%
EPS Next 2Y15.21%
EPS Next 3Y10.44%
EPS Next 5Y9.35%
Revenue Next Year-69.54%
Revenue Next 2Y-42.79%
Revenue Next 3Y-30.76%
Revenue Next 5Y15.34%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ACRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.21%
EPS Next 3Y10.44%
5. Dividend
5.1 Amount
ACRS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACLARIS THERAPEUTICS INC
NASDAQ:ACRS (5/3/2024, 7:00:00 PM)
After market: 1.38 +0.02 (+1.47%)1.36
+0.05 (+3.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap96.91M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.82% | ||
| ROE | -56.29% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.15% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.16 | ||
| Quick Ratio | 4.16 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)6.02%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y19.57%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)5.04%
Revenue growth 3Y68.95%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y